Top News
Next Story
NewsPoint

Natco pharma joins Columbia University trials using Chloroquine Phosphate to prevent Covid-19 infections

Send Push
ET Health
23rd May, 2020 16:21 IST
HYDERABAD: After becoming part of a global clinical trial using Chloroquine Phosphate by CROWN (Covid-19 Research Outcomes Worldwide Network) Collaborative at the Washington University School of Medicine in St Louis, Hyderabad-based Natco Pharma Ltd has now joined a study by New York’s Columbia University to carry out Phase-2 clinical trials using Chloroquine Phosphate to prevent symptomatic SARS-CoV-2 infections.

The trial is aimed at determining the effectiveness of CQ in preventing Covid-19 infection in healthcare workers with moderate to high risk of exposure to the virus, Natco Pharma said.

"Researchers at Columbia University are conducting this critical study to assess CQ as prophylaxis against Covid-19 in healthcare workers. The Phase 2 trial will enrol 350 volunteers, who work in direct patient care roles at Columbia University Irving Medical Center and who have been in contact with patients who may have Covid-19 infection," it said.

The company is donating the Chloroquine Phosphate tablets for the trials through its marketing partner in the United States, Rising Pharmaceuticals. NATCO has been supplying the USFDA approved drug through its marketing partner to the United States since 2011.

Follow and connect with us on Twitter, Facebook, Linkedin
Explore more on Newspoint
Loving Newspoint? Download the app now